Cheminor
This article was originally published in The Tan Sheet
Executive Summary
Receives tentative ANDA approval for OTC ranitidine 75 mg Jan. 29. Exclusivity for the branded product, Warner-Lambert's Zantac 75, expires June 19. Other firms with tentative approvals include Chelsea, Ranbaxy, Novopharm and Zenith Goldline. Novopharm was awarded 180-day generic exclusivity for being the first to submit an application. Marketing exclusivity for Zantac 75 originally was to expire Dec. 19 but was extended an additional six months due to Warner-Lambert's submission of pediatric use data for the molecule
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning